Single-agent chemotherapy for recurrent carcinoma of the cervix

R. S. Freedman, Jay Herson, J. T. Wharton, F. N. Rutledge

Research output: Contribution to journalArticle

Abstract

A randomized study of 59 patients with recurrent squamous carcinoma of the cervix originally treated with radiotherapy is reported. Patients were randomized on recurrence to either Hexamethylmelamine, Adriamycin, or Cytoxan as first agent. When analysis was restricted to 37 patients with easily evaluable disease, Cytoxan had a significantly greater response rate (23.1%, 3/13) than Hexamethylmelamine (0%, 0/14) (p=0.08). The response rate of Adriamycin was 20% (2/10). There was no evidence of a significant effect of first agent on survival time taken from the start of chemotherapy. The number of months from diagnosis to the start of chemotherapy (p=0.04) and the patients' response status (p=0.002) did however have significant effects on survival time. There was no evidence of a significant effect of first agent on survival time after treatment change but response to first agent did have a significant effect on survival (p=0.05). Hexamethylmelamine had a greater frequency of severe toxicity (50%, 10/20) than Adriamycin (10.5%, 2/19) (p=0.014) and Cytoxan (10% 2/10) (p=0.014).

Original languageEnglish (US)
Pages (from-to)345-350
Number of pages6
JournalCancer Clinical Trials
Volume3
Issue number4
StatePublished - Dec 1 1980
Externally publishedYes

Fingerprint

Altretamine
Cervix Uteri
Doxorubicin
Cyclophosphamide
Carcinoma
Drug Therapy
Survival
Squamous Cell Carcinoma
Radiotherapy
Recurrence
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Freedman, R. S., Herson, J., Wharton, J. T., & Rutledge, F. N. (1980). Single-agent chemotherapy for recurrent carcinoma of the cervix. Cancer Clinical Trials, 3(4), 345-350.

Single-agent chemotherapy for recurrent carcinoma of the cervix. / Freedman, R. S.; Herson, Jay; Wharton, J. T.; Rutledge, F. N.

In: Cancer Clinical Trials, Vol. 3, No. 4, 01.12.1980, p. 345-350.

Research output: Contribution to journalArticle

Freedman, RS, Herson, J, Wharton, JT & Rutledge, FN 1980, 'Single-agent chemotherapy for recurrent carcinoma of the cervix', Cancer Clinical Trials, vol. 3, no. 4, pp. 345-350.
Freedman RS, Herson J, Wharton JT, Rutledge FN. Single-agent chemotherapy for recurrent carcinoma of the cervix. Cancer Clinical Trials. 1980 Dec 1;3(4):345-350.
Freedman, R. S. ; Herson, Jay ; Wharton, J. T. ; Rutledge, F. N. / Single-agent chemotherapy for recurrent carcinoma of the cervix. In: Cancer Clinical Trials. 1980 ; Vol. 3, No. 4. pp. 345-350.
@article{c12197a7045c4894aab66676c4326d84,
title = "Single-agent chemotherapy for recurrent carcinoma of the cervix",
abstract = "A randomized study of 59 patients with recurrent squamous carcinoma of the cervix originally treated with radiotherapy is reported. Patients were randomized on recurrence to either Hexamethylmelamine, Adriamycin, or Cytoxan as first agent. When analysis was restricted to 37 patients with easily evaluable disease, Cytoxan had a significantly greater response rate (23.1{\%}, 3/13) than Hexamethylmelamine (0{\%}, 0/14) (p=0.08). The response rate of Adriamycin was 20{\%} (2/10). There was no evidence of a significant effect of first agent on survival time taken from the start of chemotherapy. The number of months from diagnosis to the start of chemotherapy (p=0.04) and the patients' response status (p=0.002) did however have significant effects on survival time. There was no evidence of a significant effect of first agent on survival time after treatment change but response to first agent did have a significant effect on survival (p=0.05). Hexamethylmelamine had a greater frequency of severe toxicity (50{\%}, 10/20) than Adriamycin (10.5{\%}, 2/19) (p=0.014) and Cytoxan (10{\%} 2/10) (p=0.014).",
author = "Freedman, {R. S.} and Jay Herson and Wharton, {J. T.} and Rutledge, {F. N.}",
year = "1980",
month = "12",
day = "1",
language = "English (US)",
volume = "3",
pages = "345--350",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Single-agent chemotherapy for recurrent carcinoma of the cervix

AU - Freedman, R. S.

AU - Herson, Jay

AU - Wharton, J. T.

AU - Rutledge, F. N.

PY - 1980/12/1

Y1 - 1980/12/1

N2 - A randomized study of 59 patients with recurrent squamous carcinoma of the cervix originally treated with radiotherapy is reported. Patients were randomized on recurrence to either Hexamethylmelamine, Adriamycin, or Cytoxan as first agent. When analysis was restricted to 37 patients with easily evaluable disease, Cytoxan had a significantly greater response rate (23.1%, 3/13) than Hexamethylmelamine (0%, 0/14) (p=0.08). The response rate of Adriamycin was 20% (2/10). There was no evidence of a significant effect of first agent on survival time taken from the start of chemotherapy. The number of months from diagnosis to the start of chemotherapy (p=0.04) and the patients' response status (p=0.002) did however have significant effects on survival time. There was no evidence of a significant effect of first agent on survival time after treatment change but response to first agent did have a significant effect on survival (p=0.05). Hexamethylmelamine had a greater frequency of severe toxicity (50%, 10/20) than Adriamycin (10.5%, 2/19) (p=0.014) and Cytoxan (10% 2/10) (p=0.014).

AB - A randomized study of 59 patients with recurrent squamous carcinoma of the cervix originally treated with radiotherapy is reported. Patients were randomized on recurrence to either Hexamethylmelamine, Adriamycin, or Cytoxan as first agent. When analysis was restricted to 37 patients with easily evaluable disease, Cytoxan had a significantly greater response rate (23.1%, 3/13) than Hexamethylmelamine (0%, 0/14) (p=0.08). The response rate of Adriamycin was 20% (2/10). There was no evidence of a significant effect of first agent on survival time taken from the start of chemotherapy. The number of months from diagnosis to the start of chemotherapy (p=0.04) and the patients' response status (p=0.002) did however have significant effects on survival time. There was no evidence of a significant effect of first agent on survival time after treatment change but response to first agent did have a significant effect on survival (p=0.05). Hexamethylmelamine had a greater frequency of severe toxicity (50%, 10/20) than Adriamycin (10.5%, 2/19) (p=0.014) and Cytoxan (10% 2/10) (p=0.014).

UR - http://www.scopus.com/inward/record.url?scp=0019180230&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019180230&partnerID=8YFLogxK

M3 - Article

C2 - 6775827

AN - SCOPUS:0019180230

VL - 3

SP - 345

EP - 350

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 4

ER -